SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
23 08 2022
Historique:
received: 26 11 2020
revised: 16 04 2022
accepted: 04 08 2022
entrez: 24 8 2022
pubmed: 25 8 2022
medline: 27 8 2022
Statut: ppublish

Résumé

Mutations in the splicing factor SF3B1 are frequently occurring in various cancers and drive tumor progression through the activation of cryptic splice sites in multiple genes. Recent studies also demonstrate a positive correlation between the expression levels of wild-type SF3B1 and tumor malignancy. Here, we demonstrate that SF3B1 is a hypoxia-inducible factor (HIF)-1 target gene that positively regulates HIF1 pathway activity. By physically interacting with HIF1α, SF3B1 facilitates binding of the HIF1 complex to hypoxia response elements (HREs) to activate target gene expression. To further validate the relevance of this mechanism for tumor progression, we show that a reduction in SF3B1 levels via monoallelic deletion of Sf3b1 impedes tumor formation and progression via impaired HIF signaling in a mouse model for pancreatic cancer. Our work uncovers an essential role of SF3B1 in HIF1 signaling, thereby providing a potential explanation for the link between high SF3B1 expression and aggressiveness of solid tumors.

Identifiants

pubmed: 36001976
pii: S2211-1247(22)01084-1
doi: 10.1016/j.celrep.2022.111266
pii:
doi:

Substances chimiques

Hypoxia-Inducible Factor 1 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Phosphoproteins 0
RNA Splice Sites 0
RNA Splicing Factors 0
Sf3b1 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111266

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Patrik Simmler (P)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.

Cédric Cortijo (C)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Lisa Maria Koch (LM)

Institute of Biochemistry, ETH Zurich, 8093 Zurich, Switzerland.

Patricia Galliker (P)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Silvia Angori (S)

Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.

Hella Anna Bolck (HA)

Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.

Christina Mueller (C)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Ana Vukolic (A)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Peter Mirtschink (P)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Yann Christinat (Y)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Natalie R Davidson (NR)

Department of Computer Science, ETH Zurich, 8092 Zurich, Switzerland.

Kjong-Van Lehmann (KV)

Department of Computer Science, ETH Zurich, 8092 Zurich, Switzerland.

Giovanni Pellegrini (G)

Institute of Veterinarian Science, University of Zurich, 8057 Zurich, Switzerland.

Chantal Pauli (C)

Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.

Daniela Lenggenhager (D)

Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.

Ilaria Guccini (I)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Till Ringel (T)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.

Christian Hirt (C)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.

Kim Fabiano Marquart (KF)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.

Moritz Schaefer (M)

Medical University of Vienna, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Institute of Artificial Intelligence, 1090 Vienna, Austria.

Gunnar Rätsch (G)

Department of Computer Science, ETH Zurich, 8092 Zurich, Switzerland.

Matthias Peter (M)

Institute of Biochemistry, ETH Zurich, 8093 Zurich, Switzerland.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.

Markus Stoffel (M)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Gerald Schwank (G)

Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland. Electronic address: schwank@pharma.uzh.ch.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH